WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's health

Amid shifts in attitudes around family planning and contraception—and as the advent telehealth outfits like Hims & Hers and Ro define a new era of consumer-driven healthcare—the lack of a medic | Recognizing the gap in male birth control, Charlottesville, Virginia’s Contraline is stepping up to the plate, developing what it believes could be a first-in-class topical candidate that has now garnered enthusiasm from a host of big-name investors.

Raccontata dafiercepharma.comendpoints.newspharmaceutical-technology.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
fiercepharma.comStai leggendo1 mese fa

Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's…

Contraline raised $92.5M Series B to advance NES/T Gel, a first-in-class topical male contraceptive, into phase 3 trials starting 2027. The round signals VC appetite for consumer-driven healthcare in underserved categories, positioning potential telehealth distribution.

originale

Timeline cronologica

  1. martedì 2 giugno 2026·fiercepharma.com

    Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's health

    Amid shifts in attitudes around family planning and contraception—and as the advent telehealth outfits like Hims & Hers and Ro define a new era of consumer-driven healthcare—the…

  2. martedì 2 giugno 2026·endpoints.news

    Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

    Contraline closes $92.5M Series B to fund male contraception; Novartis begins Phase 3 actinium therapies; Tavo gets $17M Series A.

pharmaceutical-technology.com1 mese fa

Contraline secures $92.5m to push male contraceptive into late-stage trials - Pharmaceutical Technology

Contraline closes $92.5M Series B to advance male contraceptive NES/T to Phase III, targeting 2027 FDA approval. The funding demonstrates VC interest in complex-regulated biotech, signaling capital flows beyond software—relevant context for startup-ecosystem diversification.

Leggi questa versione → originale
endpoints.news1 mese fa

Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

Contraline closes $92.5M Series B to fund male contraception; Novartis begins Phase 3 actinium therapies; Tavo gets $17M Series A.

Leggi questa versione → originale
  • mercoledì 3 giugno 2026·pharmaceutical-technology.com

    Contraline secures $92.5m to push male contraceptive into late-stage trials - Pharmaceutical Technology

    Contraline could become the first to commercialise a reversible male contraceptive drug, provided the treatment is successful in Phase III.